PMID- 17047932
OWN - NLM
STAT- MEDLINE
DCOM- 20070302
LR  - 20221207
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 189
IP  - 4
DP  - 2007 Jan
TI  - The effects of fluoxetine on the subjective and physiological effects of 
      3,4-methylenedioxymethamphetamine (MDMA) in humans.
PG  - 565-73
AB  - OBJECTIVE: The purpose of this study was to investigate the role of serotonin 
      (5-HT) in the effects of oral 3,4-methylenedioxymethamphetamine (MDMA) in humans. 
      MATERIALS AND METHODS: The subjective and physiological effects of 1.5 mg/kg MDMA 
      were evaluated after 20 mg fluoxetine in eight recreational MDMA users in a 
      double-blind, placebo-controlled study. During phase 1, participants were 
      maintained on placebo for at least 5 days and tested with MDMA and placebo on 
      separate sessions. In phase 2, the procedure was the same except fluoxetine was 
      administered daily for at least 5 days. During sessions, placebo or fluoxetine 
      was given 1 h before the session drug and effects were measured over the next 7 
      h. RESULTS: MDMA increased positive-like subjective effects on all the Addiction 
      Research Center Inventory scales; Arousal, Elation, Positive Mood, and Vigor on 
      the Profile of Mood States; Drug Liking, Friendly, Good Drug Effect, High, 
      Stimulated, and Talkative on the Visual Analog Scale; and End-of-Session Liking 
      and Crossover Point on the Multiple Choice Procedure. MDMA also increased 
      measures of anxiety. On the Hallucinogenic Rating Scale, all scales except 
      Volition were increased. MDMA also increased blood pressure and heart rate. 
      Fluoxetine treatment attenuated most of the positive-like subjective effects 
      including the Affect and Soma scales of the Hallucinogen Rating Scale. In 
      addition, heart rate but not blood pressure increases were reduced. CONCLUSIONS: 
      These results suggest that blockade of 5-HT reuptake by fluoxetine can dampen the 
      effects of MDMA and further supports the role of 5-HT in its behavioral effects 
      in humans.
FAU - Tancer, Manuel
AU  - Tancer M
AD  - Department of Psychiatry and Behavioral Neurosciences, Wayne State University, 
      2761 E. Jefferson St., Detroit, MI 48207, USA.
FAU - Johanson, Chris-Ellyn
AU  - Johanson CE
LA  - eng
GR  - KO8 DA00370/DA/NIDA NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20061018
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Affect/drug effects
MH  - Behavior/*drug effects
MH  - Blood Pressure/drug effects
MH  - Cardiovascular Physiological Phenomena/*drug effects
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Female
MH  - Fluoxetine/*pharmacology
MH  - Hallucinogens/pharmacology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Male
MH  - Mental Processes/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Serotonin Agents/*pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/*pharmacology
EDAT- 2006/10/19 09:00
MHDA- 2007/03/03 09:00
CRDT- 2006/10/19 09:00
PHST- 2006/07/13 00:00 [received]
PHST- 2006/08/17 00:00 [accepted]
PHST- 2006/10/19 09:00 [pubmed]
PHST- 2007/03/03 09:00 [medline]
PHST- 2006/10/19 09:00 [entrez]
AID - 10.1007/s00213-006-0576-z [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2007 Jan;189(4):565-73. doi: 
      10.1007/s00213-006-0576-z. Epub 2006 Oct 18.